<?xml version="1.0" encoding="UTF-8"?>
<document id="28837258">
	<sentence id="s1" text="Collagen type 4 alpha 1 (branching involved in blood vessel morphogenesis) and collagen type 13 alpha 1 (cell-matrix adhesion) produced by urothelial cancer cells support the vital oncogenic property of tumor invasion.">
		<entity id="s1.e1" charOffset="25-73"
			type="GO" text="branching involved in blood vessel morphogenesis" ontology_id="GO_0001569"/>
		<entity id="s1.e2" charOffset="105-125"
			type="GO" text="cell-matrix adhesion" ontology_id="GO_0007160"/>
		<entity id="s1.e3" charOffset="137-143"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<entity id="s1.e4" charOffset="190-195"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<pair id="s1.p1" e1="s1.e1"
		    e2="s1.e3" pgr="false"/>
		<pair id="s1.p2" e1="s1.e2"
		    e2="s1.e3" pgr="false"/>
		<pair id="s1.p3" e1="s1.e1"
		    e2="s1.e4" pgr="false"/>
		<pair id="s1.p4" e1="s1.e2"
		    e2="s1.e6" pgr="false"/>
	</sentence>
	<sentence id="s2" text="We investigated the diagnostic and prognostic capability of branching involved in blood vessel morphogenesis and cell-matrix adhesion in voided urine and compared the observed values with those of fragments of cytokeratin-19 (CYFRA21-1), nuclear matrix protein 22 (NMP-22), and voided urine cytology in bladder cancer (BCa).">
		<entity id="s2.e1" charOffset="60-108"
			type="GO" text="branching involved in blood vessel morphogenesis" ontology_id="GO_0001569"/>
		<entity id="s2.e2" charOffset="113-133"
			type="GO" text="cell-matrix adhesion" ontology_id="GO_00011360"/>
		<entity id="s2.e3" charOffset="298-304"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<pair id="s2.p1" e1="s2.e1"
		    e2="s2.e3" pgr="false"/>
		<pair id="s2.p2" e1="s2.e2"
		    e2="s2.e3" pgr="false"/>
	</sentence>
	<sentence id="s3" text="Among these biomarkers, the optimal cut-off value of branching involved in blood vessel morphogenesis + cell-matrix adhesion at 1.33 ng/mL resulted in 57.4%, 83.7%, 56.1%, 80.7%, and 91.7% sensitivity for low-grade tumors, high-grade tumors, Ta, T1, and muscle invasive disease, respectively.">
		<entity id="s3.e1" charOffset="53-101"
			type="GO" text="branching involved in blood vessel morphogenesis" ontology_id="GO_0001569"/>
		<entity id="s3.e2" charOffset="104-124"
			type="GO" text="cell-matrix adhesion" ontology_id="GO_0007160"/>
		<entity id="s3.e3" charOffset="202-207"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<pair id="s3.p1" e1="s3.e1"
		    e2="s3.e3" pgr="false"/>
		<pair id="s3.p2" e1="s3.e2"
		    e2="s3.e3" pgr="false"/>
	</sentence>
</document>
